Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Biohaven enrols first patient in Phase III rimegepant trial

Biohaven’s Phase III trial intends to enrol adult subjects who have suffered from migraine for at least one year. Credit: tara hunt.



  • Biohaven

Go Top